Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.35 |
| ▸ | TTPA | P49638 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apc-100 SCHEMBL633424 | 0.84 | CYP3A4 (0.64) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL13592377 | 0.84 | PTGS1 (0.41) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL23692505 | 0.84 | PTGS1 (0.41) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL12434165 | 0.83 | PTGS1 (0.40) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL6522953 | 0.81 | PTGS1 (0.39) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL10238653 | 0.81 | CYP1A2 (0.39) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL14313912 | 0.80 | PTGS1 (0.41) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL12512655 | 0.80 | PTGS1 (0.41) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL7875364 | 0.80 | HPGD (0.38) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL7863378 | 0.80 | PTGS1 (0.35) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018142131-A1 | OIL TAGGING | Forecast Technology Limited (GB) | 2018-08-09 | — | — | WO | disclosed |
| US-20160075651-A1 | GLYCOLIPID INHIBITION USING IMINOSUGARS | UNITHER VIROLOGY, LLC (US) | 2016-03-17 | — | — | US | disclosed |
| US-8921568-B2 | Iminosugars and their applications | UNITHER VIROLOGY, LLC (US) | 2014-12-30 | — | — | US | disclosed |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | ASTELLAS PHARMA INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | ASTELLAS PHARMA INC. | 2011-03-24 | — | — | US | disclosed |
| EP-2279757-A2 | Compounds for targeting endothelial cells | Bracco Suisse SA (CH) | 2011-02-02 | — | — | EP | disclosed |
| US-7855225-B2 | 17βHSD type 5 inhibitor | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7855225-B2 | 17βHSD type 5 inhibitor | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| EP-2228364-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | Novartis AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-7482462-B2 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-7482462-B2 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1455777-B1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-03-15 | — | — | US | disclosed |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | disclosed |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-11 | — | — | US | disclosed |
| WO-2006097293-A2 | COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| WO-2003055478-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | STS, ARSA, CYP17A1 | PTGS1 3054/4885PTGS2 3680/4885CYP1A2 707/4885 |
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | HTR6, NPY5R, NPY2R | PTGS1 750/4885PTGS2 1137/4885CYP1A2 3099/4885 |
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | CYP17A1, HSD17B3, HSD3B1 | PTGS1 730/4885PTGS2 1449/4885CYP1A2 389/4885 |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | HTR6, HTR5A, P2RX6 | PTGS1 207/4885PTGS2 361/4885CYP1A2 299/4885 |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, NPY5R, NPY2R | PTGS1 750/4885PTGS2 1137/4885CYP1A2 3099/4885 |
| US-20160075651-A1 | GLYCOLIPID INHIBITION USING IMINOSUGARS | UGCG, UGGT1, DGAT1 | PTGS1 2201/4885PTGS2 2233/4885CYP1A2 3264/4885 |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | NPY5R, HTR6, NPY2R | PTGS1 657/4885PTGS2 1040/4885CYP1A2 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.